Who is sponsoring NCT03824860?

NCT03824860 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT03824860?

Interventions in NCT03824860: Yoga.

What condition does NCT03824860 study?

NCT03824860 studies Chemotherapy-induced Peripheral Neuropathy, Yoga, Chronic Pain, Neuropathic Pain.

Is NCT03824860 still recruiting?

NCT03824860 is currently completed. Last updated 28 March 2022.

Last reviewed 2022-03-28 · How we verify

NCT03824860

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study

Completed NA Last updated 28 March 2022

What this trial tests

NA trial testing Yoga in Chemotherapy-induced Peripheral Neuropathy in 47 participants. Completed in 18 February 2021.

Timeline

6 August 2019

Primary endpoint
8 February 2021

18 February 2021

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	47
Start date	6 August 2019
Primary completion	8 February 2021
Estimated completion	18 February 2021
Sites	1 location across United States

Drugs / interventions tested

Yoga

Conditions studied

Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
Yoga — all drugs for Yoga →
Chronic Pain — all drugs for Chronic Pain →
Neuropathic Pain — all drugs for Neuropathic Pain →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy or Yoga. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study will examine the feasibility of conducting an eight-week yoga intervention for individuals with chronic painful chemotherapy-induced peripheral neuropathy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial.
Knoerl R, Giobbie-Hurder A, Berfield J, Berry D, et al · · 2022 · cited 30× · PMID 34524631 · DOI 10.1007/s11764-021-01081-z
Lessons learned from the delivery of virtual integrative oncology interventions in clinical practice and research during the COVID-19 pandemic.
Knoerl R, Phillips CS, Berfield J, Woods H, et al · · 2021 · cited 23× · PMID 33772364 · DOI 10.1007/s00520-021-06174-0

Verify or expand the search:

Other trials of Yoga

Trials testing the same drug.

NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
NCT07485790 — The Effects of Yoga on Pregnant Women · NA · recruiting
NCT07480174 — Effects of Tai Chi and Yoga on Flexibility, Anxiety, and Sleep Quality in Women · NA · recruiting
NCT06949007 — Yoga for Persistent Post-Surgical Pain (PPSP) · NA · recruiting
NCT07415850 — The Effect of a Four-Week Hatha Yoga Intervention to Improve Quality of Life, Anxiety, and Depressive Symptoms in Indivi · NA · not yet recruiting

Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy

Currently open trials in the same condition.

NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03824860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 28 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03824860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing